research 7288 A Preclinical Mouse Model of Gender-Affirming Hormone Therapy: Metabolic and Behavioral Outcomes
Gender-affirming hormone therapy affects metabolism differently based on treatment type.
Search
for
Sort by
Research
660-690 / 1000+ results 
research Clinical Utility of GnRH Analogues in Female Androgen Excess: Highlighting Diagnostic and Therapeutic Applications
GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.
research Spironolactone Reduces Facial and Body Hair in Women with Hirsutism
Spironolactone helps reduce hair growth in women with hirsutism but may cause menstrual irregularities.
research Effects of 5-alpha reductase inhibitors
5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
research Sex Hormones and Related Compounds, Including Hormonal Contraceptives
Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.
research Iperandrogenismo della donna in menopausa
A 77-year-old woman with hair loss had high testosterone and 17OH-progesterone levels, but no significant findings on imaging.
research Ovarian intratumoral 21-hydroxylase deficiency in a postmenopausal hirsute woman
A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.
research Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Novel Drugs Targeting Retinoic Acid Receptors
Newer retinoid drugs are effective for skin conditions but have significant side effects.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research Corticotropin releasing factor-1 receptor antagonism associated with favorable outcomes of male reproductive health biochemical parameters
Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
research The efficacy of an adjuvant norethisterone (jenapharm) therapy in endometrial cancer
Norethisterone (jenapharm) therapy is effective for endometrial cancer.
research Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study.
Both oral contraceptives reduced hirsutism in PCOS patients, but adding metformin showed no extra benefit.
research Compounded Testosterone Troches TO OPTIMIZE HEALTH AND THE TESTOSTERONE CONTROVERSY.
Properly administered testosterone therapy is safe and effective but often not covered by insurance.
research Serious complication of low-dose oral minoxidil for hair loss
Low-dose oral minoxidil can cause serious heart complications.
research Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS ) With a Focus on Pericardial Effusions
Low-dose oral minoxidil can cause serious side effects like heart issues, so use the lowest effective dose.
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research Impaired Cardiometabolic Effects of Bromocriptine in Men With Early‐Onset Androgenic Alopecia
Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
research Effects of In Utero Exposure to D-004, a Lipid Extract from Roystonea regia Fruits, in the Male Rat: A Comparison with Finasteride
D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
research (423) A Case Series of Successful Off-label Use of Flibanserin
Flibanserin may help improve sexual symptoms in various conditions beyond its approved use.
research Hormonal Treatment of Transgender Women with Oral Estradiol
Oral estradiol works for many transgender women but needs personalized dosing and monitoring.
research A comparison between flutamide and finasteride plus flutamide combination in the treatment of hirsutism
Flutamide alone is as effective as the combination with finasteride for treating hirsutism.
research Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes
Testosterone pellets may help women's sexual function but have safety concerns and need more research.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research Estrogenic Potential of 2-Alkyl-4-(thio)chromenone 6-O-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase
A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.
research Testosterone replacement in the setting of Finasteride therapy: a therapeutic dilemma
research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
research Ovarian Stromal Hyperthecosis and Hyperandrogenemia Refractory to Hormonal Suppression
Removing both ovaries may better treat increased male hormone levels and related symptoms in postmenopausal women when hormone therapy doesn't work.
research Pharmacological Profile of 9,11-Dehydrocortexolone 17α-Butyrate (CB-03-04), a New Androgen Antagonist with Antigonadotropic Activity
CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.